BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Symbol: BBIO on Nasdaq
Shares outstanding: 193,828,463
Price per share: $76.84
All holders as of 31 Dec 2025: Q4 2025
Total 13F shares: 97,668,418
Total reported value: $7,478,665,997
% of total 13F portfolios: 0.02%
Share change: -1,480,135
Value change: -$43,380,432
Number of holders: 314
Price from insider filings: $76.84

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
VANGUARD GROUP INC	8.7%		$711,821,652		16,484,985		The Vanguard Group	30 Jun 2025
VIKING GLOBAL INVESTORS LP	8.2%	-15%	$825,530,932	-$140,704,733	15,893,934	-15%	VIKING GLOBAL INVESTORS LP	14 Nov 2025
KKR Genetic Disorder L.P.	7%	-31%	$476,864,517	-$215,760,000	13,260,971	-31%	KKR Genetic Disorder L.P.	12 May 2025
Kumar Neil	5.4%		$376,382,964		10,466,712		NEIL KUMAR	31 Dec 2024

As of 31 Dec 2025, 314 institutional investors reported holding 97,668,418 shares of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO). This represents 50% of the company’s total 193,828,463 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution	Ownership %	Shares Held	Share Change %	Portfolio %	Holdings Value
VANGUARD GROUP INC	8.7%	16,862,691	+0.18%	0.02%	$1,289,827,235
BlackRock, Inc.	7.5%	14,549,529	+0.96%	0.02%	$1,112,893,458
Kohlberg Kravis Roberts & Co. L.P.	6.8%	13,260,971	0%	16%	$1,014,331,672
JANUS HENDERSON GROUP PLC	5.7%	11,000,457	+26%	0.38%	$841,348,639
FARALLON CAPITAL MANAGEMENT LLC	4.6%	8,998,463	+9.8%	4%	$688,292,435
Aisling Capital Management LP	2.6%	5,089,611	-16%	81%	$389,304,345
STATE STREET CORP	2.6%	4,962,866	-11%	0.01%	$379,609,620
GEODE CAPITAL MANAGEMENT, LLC	2.3%	4,412,523	+13%	0.02%	$344,688,555
PRICE T ROWE ASSOCIATES INC /MD/	2%	3,828,746	+144%	0.03%	$292,862,000
Frazier Life Sciences Management, L.P.	1.8%	3,545,557	-7.8%	7.3%	$271,199,655
WELLINGTON MANAGEMENT GROUP LLP	1.2%	2,348,731	+130%	0.03%	$179,654,434
FRANKLIN RESOURCES INC	1.1%	2,164,928	+50%	0.04%	$165,595,356
MANUFACTURERS LIFE INSURANCE COMPANY, THE	1%	1,975,315	+3.2%	0.12%	$151,011,883
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	1%	1,964,419	+2%	0.02%	$150,258,409
Capital Research Global Investors	1%	1,934,698	+0.08%	0.03%	$147,985,050
UBS Group AG	0.97%	1,875,665	-27%	0.03%	$143,469,616
SC US (TTGP), LTD.	0.96%	1,860,364	0%	1%	$142,299,242
GOLDMAN SACHS GROUP INC	0.92%	1,782,833	-19%	0.02%	$136,368,897
Driehaus Capital Management LLC	0.87%	1,680,972	+1.1%	0.87%	$128,577,548
BNP PARIBAS FINANCIAL MARKETS	0.82%	1,592,660	0%	0.08%	$121,822,563
NORGES BANK	0.79%	1,527,028		0.01%	$116,802,372
Laurion Capital Management LP	0.72%	1,402,150	-20%	7.3%	$107,250,453
MORGAN STANLEY	0.72%	1,399,809	+33%	0.01%	$107,071,416
NORTHERN TRUST CORP	0.69%	1,346,754	-4%	0.01%	$103,013,214
PRINCIPAL FINANCIAL GROUP INC	0.68%	1,314,303	+3.7%	0.05%	$100,531,037

Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	97,668,418	$7,478,665,997	-$43,380,432	$44,616,617	$569,108,006	$76.49	314
2025 Q3	184,964,456	$9,606,990,342	-$158,354,848	$95,310,452	$585,114,262	$51.94	389
2025 Q2	188,818,044	$8,154,464,813	+$171,957,099	$95,078,274	$484,993,166	$43.18	357
2025 Q1	185,173,982	$6,405,659,483	+$325,204,372	$72,291,862	$441,052,155	$34.57	302
2024 Q4	176,645,317	$4,847,193,349	+$87,655,048	$68,033,556	$354,464,324	$27.44	260
2024 Q3	172,596,886	$4,393,814,683	-$68,086,150	$60,246,408	$264,161,420	$25.46	251
2024 Q2	174,953,530	$4,431,556,073	+$57,307,408	$69,984,256	$216,720,947	$25.33	249
2024 Q1	171,539,419	$5,303,582,949	+$162,256,099	$79,223,644	$225,435,028	$30.92	240
2023 Q4	165,715,337	$6,690,573,516	+$142,779,397	$80,602,337	$64,217,522	$40.37	246
2023 Q3	161,102,840	$4,243,730,776	+$304,390,990	$42,848,613	$52,895,583	$26.37	219
2023 Q2	149,815,028	$2,576,329,186	-$39,862,601	$73,795,250	$98,670,016	$17.20	196
2023 Q1	152,372,388	$2,526,139,807	+$155,256,748	$27,808,632	$38,637,658	$16.58	210
2022 Q4	144,623,389	$1,101,997,850	-$14,634,842	$443,484	$1,069,396	$7.62	175
2022 Q3	145,248,661	$1,443,911,522	+$48,733,339	$1,750,000	$1,953,000	$9.94	170
2022 Q2	140,449,294	$1,275,283,327	-$23,547,672	$2,581,000	$5,787,000	$9.08	153
2022 Q1	143,303,557	$1,454,787,082	-$23,988,513	$3,746,000	$7,228,000	$10.15	167
2021 Q4	141,976,495	$2,367,117,577	-$117,448,257	$63,701,308	$108,846,716	$16.68	181
2021 Q3	140,028,398	$6,563,888,337	-$165,004,819	$34,998,500	$18,756,000	$46.87	206
2021 Q2	142,676,491	$8,697,122,835	+$97,636,690	$43,272,000	$18,194,000	$60.96	197
2021 Q1	141,085,070	$8,688,930,801	+$1,238,074,220	$38,743,000	$18,280,000	$61.60	194
2020 Q4	121,079,579	$8,609,553,572	+$172,667,185	$8,027,000	$23,212,000	$71.11	160
2020 Q3	117,841,767	$4,393,419,330	+$21,644,575	$1,647,000	$1,709,000	$37.52	128
2020 Q2	117,300,177	$3,824,660,106	+$145,729,688	$558,000	$23,083,000	$32.61	114
2020 Q1	112,894,365	$3,273,779,385	+$162,480,179	$1,760,000	$9,715,000	$29.00	93
2019 Q4	100,520,271	$3,523,336,508	+$149,163,509			$35.05	85
2019 Q3	103,303,295	$2,217,864,724	+$112,320,073			$21.47	75
2019 Q2	99,927,998	$2,695,534,750	+$2,695,534,740			$26.97	60